KRAS mutations predict shorter survival in lung cancer

KRAS mutations predict shorter survival in lung cancer
For patients with advanced lung adenocarcinomas, KRAS mutations predict shorter survival, according to a study published online July 18 in Cancer.

(HealthDay) -- For patients with advanced lung adenocarcinomas, KRAS mutations predict shorter survival, according to a study published online July 18 in Cancer.

Melissa L. Johnson, M.D., from Northwestern University in Chicago, and colleagues examined the prognostic significance of KRAS using data from 1,036 patients (59 percent women; 33 percent never-smokers) with advanced lung adenocarcinomas with known and KRAS status, who were evaluated between 2002 and 2009.

The researchers found that the patients had a median age of 65 years, and 81 percent had a Karnofsky performance status of 80 percent or greater. EGFR mutations correlated with longer overall survival (hazard ratio, 0.60; P < 0.001) and KRAS mutations with shorter survival (hazard ratio, 1.21; P = 0.048), in multivariate analysis.

"In conclusion, we report here that the presence of a KRAS mutation is a poor for patients with lung adenocarcinomas," the authors write. "Because patients with KRAS mutations have a distinct clinical course that results in shorter survival, they should be evaluated separately in clinical trials. We recommend including KRAS testing in upfront mutation analyses along with testing for EGFR mutations and EML4-ALK to prospectively identify these patients in the clinic."

Several authors disclosed to pharmaceutical companies.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Antifolates show promise against NSCLC subtype

Nov 14, 2011

Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs, according to results of a recent study conducted by Quintiles comparing human lung cancer ...

Gene-based test identifies poor-prognosis colon cancers

Mar 09, 2012

(HealthDay) -- A sensitive and specific gene-based classifier can be used to identify BRAF mutant colon cancer tumors and a subpopulation of BRAF wild-type tumors with poor prognosis, according to a study pu ...

Recommended for you

User comments